A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.

IF 3.5 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Rui Ma, Yanyan Liu, Baolong Ding, Yuyang Sun, Hongting Yao, Man Yu, Xiaoye Wang, Lingli Zhang, Xin Li
{"title":"A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.","authors":"Rui Ma, Yanyan Liu, Baolong Ding, Yuyang Sun, Hongting Yao, Man Yu, Xiaoye Wang, Lingli Zhang, Xin Li","doi":"10.1186/s12889-025-23570-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The emergence of innovative anticancer medicines has revitalized cancer treatment prospects, and improving the accessibility of innovative anticancer medicines is a key goal of national pharmaceutical policies. Despite significant efforts by the National Medical Security Administration to reform the National Reimbursement Drug List (NRDL), concerns regarding the utilization of these newly included anticancer drugs persist. This study aims to assess the accessibility of 23 Innovative Negotiated Anticancer Medicines (INAMs) in Jiangsu Province, a developed region in eastern China.</p><p><strong>Methods: </strong>A retrospective survey was conducted across 319 healthcare institutions in Jiangsu Province, with 285 included for analysis. Data were obtained from procurement records of 23 INAMs. We evaluated the use of these medicines based on three aspects: availability, price measured by the defined daily dose cost (DDDc), and affordability.</p><p><strong>Results: </strong>43.5% of the 23 INAMs encountered difficulties in obtaining them, and 30.4% of 23 INAMs were very difficult to obtain. There was a notable disparity in the availability of 23 INAMs between secondary and tertiary healthcare institutions. The median DDDc for Group A and Group C showed a progressive annual reduction. The DDDc of 19 INAMs decreased during the study period, while three drugs remained unchanged, and one drug's DDDc actually increased. Family poverty caused by medicines was more pronounced among rural residents. The affordability of rural patients was significantly lower than that of urban patients (p < 0.05) in 2021 and 2022.</p><p><strong>Conclusion: </strong>The accessibility of INAMs improved from 2020 to 2022. However, the accessibility of INAMs is influenced by various factors, and disparities still exist in access across different healthcare institutions and between urban and rural areas. Effective and sustainable policies need to be developed to ensure equitable access to medicines for all patients.</p>","PeriodicalId":9039,"journal":{"name":"BMC Public Health","volume":"25 1","pages":"2313"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12889-025-23570-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The emergence of innovative anticancer medicines has revitalized cancer treatment prospects, and improving the accessibility of innovative anticancer medicines is a key goal of national pharmaceutical policies. Despite significant efforts by the National Medical Security Administration to reform the National Reimbursement Drug List (NRDL), concerns regarding the utilization of these newly included anticancer drugs persist. This study aims to assess the accessibility of 23 Innovative Negotiated Anticancer Medicines (INAMs) in Jiangsu Province, a developed region in eastern China.

Methods: A retrospective survey was conducted across 319 healthcare institutions in Jiangsu Province, with 285 included for analysis. Data were obtained from procurement records of 23 INAMs. We evaluated the use of these medicines based on three aspects: availability, price measured by the defined daily dose cost (DDDc), and affordability.

Results: 43.5% of the 23 INAMs encountered difficulties in obtaining them, and 30.4% of 23 INAMs were very difficult to obtain. There was a notable disparity in the availability of 23 INAMs between secondary and tertiary healthcare institutions. The median DDDc for Group A and Group C showed a progressive annual reduction. The DDDc of 19 INAMs decreased during the study period, while three drugs remained unchanged, and one drug's DDDc actually increased. Family poverty caused by medicines was more pronounced among rural residents. The affordability of rural patients was significantly lower than that of urban patients (p < 0.05) in 2021 and 2022.

Conclusion: The accessibility of INAMs improved from 2020 to 2022. However, the accessibility of INAMs is influenced by various factors, and disparities still exist in access across different healthcare institutions and between urban and rural areas. Effective and sustainable policies need to be developed to ensure equitable access to medicines for all patients.

创新协商抗癌药的可得性、价格和可负担性调查:中国东部江苏省的回顾性研究
背景:创新抗癌药物的出现为癌症治疗前景注入了新的活力,提高创新抗癌药物的可及性是国家医药政策的重要目标。尽管国家医疗保障局在改革国家报销药品目录(NRDL)方面做出了重大努力,但对这些新纳入的抗癌药物的使用仍然存在担忧。本研究旨在评估中国东部经济发达地区江苏省23种创新协商抗肿瘤药物(INAMs)的可及性。方法:对江苏省319家医疗卫生机构进行回顾性调查,其中285家进行分析。数据来自23家inam的采购记录。我们从三个方面评估了这些药物的使用情况:可获得性、以限定日剂量成本(DDDc)衡量的价格和可负担性。结果:23例inam中有43.5%的人难以获得,30.4%的人非常难以获得。在二级和三级保健机构之间,有23个国家医疗护理人员的可用性存在显著差异。A组和C组的中位DDDc呈逐年递减趋势。19种INAMs的DDDc在研究期间有所下降,3种药物的DDDc保持不变,有一种药物的DDDc实际上有所增加。药品导致的家庭贫困在农村居民中更为明显。结论:2020 - 2022年,农村患者可负担性明显低于城市患者。然而,国家免疫系统的可及性受到各种因素的影响,不同医疗机构之间以及城乡之间在可及性方面仍然存在差距。需要制定有效和可持续的政策,以确保所有患者公平获得药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Public Health
BMC Public Health 医学-公共卫生、环境卫生与职业卫生
CiteScore
6.50
自引率
4.40%
发文量
2108
审稿时长
1 months
期刊介绍: BMC Public Health is an open access, peer-reviewed journal that considers articles on the epidemiology of disease and the understanding of all aspects of public health. The journal has a special focus on the social determinants of health, the environmental, behavioral, and occupational correlates of health and disease, and the impact of health policies, practices and interventions on the community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信